BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 21741639)

  • 1. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
    Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
    Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
    Gerson L; Lin OS
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
    Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening and surveillance of Barrett's esophagus.
    Regula J
    Dig Dis; 2009; 27(1):54-7. PubMed ID: 19439961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic screening for gastric cancer.
    Dan YY; So JB; Yeoh KG
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale for screening and surveillance of Barrett's metaplasia.
    Wani S; Sharma P
    Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
    Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
    Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommended endoscopic surveillance of patients with Barrett's esophagus (BE) is a cost-effective strategy?].
    Remes-Troche JM; Ramírez-Arias JF; Gómez-Escudero O; Valdovinos-Andraca F; Vargas-Vorácková F
    Rev Gastroenterol Mex; 2006; 71(1):46-54. PubMed ID: 17061478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus.
    Inadomi JM
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):51-63. PubMed ID: 25743456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
    Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
    Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barrett's esophagus surveillance: When, how often, does it work?
    Katona BW; Falk GW
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):9-24. PubMed ID: 21112494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?
    Soni A; Sampliner RE; Sonnenberg A
    Am J Gastroenterol; 2000 Aug; 95(8):2086-93. PubMed ID: 10950062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.